Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523872-22-00

Acronym

NRG5051-101

Enrollment

110

Registered

2025-11-17

Start date

2025-11-18

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026